Title: <u>Patient-Reported Outcomes</u> Correlate with <u>Clinical Outcomes</u> in Patients with

Idiopathic Pulmonary Fibrosis

Authors and affiliations: *Soumik Purkayastha[1,2], Suha Kadura[3], Cathie Spino[4],*

*Ganesh Raghu[*3].*

[1]Department of Biostatistics and Health Data Science, University of Pittsburgh,

Pittsburgh, PA, USA.

[2]Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System,

US Department of Veterans Affairs, Pittsburgh, PA, USA.

[3]Division of Pulmonary, Critical Care and Sleep Medicine, Center for Interstitial Lung

Diseases, Department of Medicine, University of Washington, Seattle, WA, USA

[4]Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

[*]**Corresponding author:**

Ganesh Raghu, University of Washington, Campus Box 356175, Seattle, WA 98195,

USA. Email: <u>graghu@uw.edu</u>

Contributions:

1. *Soumik Purkayastha:* Data analyses, interpretation of result, writing first draft,

revised versions and collated inputs from all authors of the manuscript.

2. *Suha Kadura:* Data gathering, interpretation of result, writing first draft, revised

versions and collated inputs from all authors of the manuscript.

3. *Cathie Spino:* Reviewed data analyses and interpretation, reviewed manuscript

and provided input.

23  4. *Ganesh Raghu:* Designed the trial and study protocol, enrolled consenting

24    participants in the study, interpretation of results, supervised the conduct of trial

25    and execution of the trial; manuscript writing.

26 **All authors reviewed the drafts of manuscript, provided input, contributed to**

27 **writing the manuscript and approved the final letter for submission.**

28   **ABSTRACT**

Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive

fibrosis and declining quality of life. Patient-reported outcomes (PROs) provide a

comprehensive understanding of a patient's experience and health status than clinical

measures (COs) alone, capturing how patients feel, function, and experience their

health. However, the relationship between PROs and COs remains incompletely

understood in this population.

Methods: We performed a secondary analysis of data from the YES-IPF trial,

examining 60 IPF patients who completed a 12-week modified yoga program or

continued usual activities. Pearson correlations between 21 PROs and 6 COs (FVC:

absolute and percent-predicted, DLCO: absolute and percent-predicted, 6-minute walk

test, and GAP: Gender-Age-Physiology index) were assessed at baseline and week. p-

values were adjusted using the Benjamini-Hochberg method across 21 PROs for each

CO measured.

Findings: Several significant correlations were observed between PROs and COs; key

findings include total L-IPF correlating with absolute FVC having baseline $r = -0.33$

$(p = 0.03)$ and 12-week $r = 0.42 \, (p < 0.01)$, total L-IPF correlating with 6MWT having

baseline $r = -0.43 \, (p < 0.01)$ and 12-week $r = -0.37 \, (p = 0.02)$, shortness of breath

R-scale-PF correlating with absolute DLCO having baseline $r = -0.35 \, (p = 0.04)$ and

12-week $r = -0.49 \, (p < 0.01)$, total KBILD correlating with percent-predicted FVC

having baseline $r = 0.38 \, (p = 0.03)$ and 12-week $r = 0.43 \, (p < 0.01)$, and K-BILD

Breathlessness and Activities score correlating with GAP score having baseline

$r = -0.42 \, (p = 0.02)$ and 12-week $r = -0.40 \, (p = 0.02)$.

Interpretation: In IPF patients, breathlessness-specific PROs report correlation with

COs of disease severity, while sleep-related and psychological domains demonstrate

weaker correlations. This highlights that PROs and COs measure related but distinct

aspects of IPF.

Funding: No funding support was received for this study.

Trial Registration: Registered with ClinicalTrials.gov (NCT0284862)

 MAIN TEXT

Idiopathic pulmonary fibrosis is a progressive lung disease significantly impacting

patients' quality of life. Patient-reported outcomes are increasingly recognized for their

ability to capture patient experience of health, encompassing how they feel and

function, which may not be reflected by clinical outcomes alone [1]. Understanding the

physical, emotional, and social impacts of patients with idiopathic pulmonary fibrosis,

including the well-established burdens of dyspnea and cough, and the increasing

recognition of fatigue, is paramount [1,2]. While both patient-reported and clinical

outcomes are valuable, patient-reported outcomes have not correlated with disease

progression, defined as decline in forced vital capacity in patients with idiopathic

pulmonary fibrosis in clinical trials to date.

The Yoga Effect on Quality-of-Life Study Among Patients with Idiopathic Pulmonary

Fibrosis (YES-IPF) trial demonstrated that a 12-week modified yoga program improved

patient-reported outcomes in patients with idiopathic pulmonary fibrosis, without

concurrent significant changes in clinical outcomes like forced vital capacity [3]. This

prompted us to explore baseline as well as week 12 correlations for all patient-reported

and clinical outcomes measured in the trial.

We analyzed data from 60 participants with well-defined idiopathic pulmonary fibrosis in

accordance with the established criteria for diagnosis [4] who participated in the YES-IPF

trial (ClinicalTrials.gov: NCT02848625). We pooled participants from the modified yoga

and control group for all analyses. Descriptive statistics for these outcomes are

presented in <u>Table 1</u>. Next, we computed pairwise Pearson correlations between 21

patient-reported outcomes (derived from seven validated instruments: the *Living with*

Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire [2,3,5], *Raghu-Scale for Pulmonary*

Fibrosis (R-scale-PF) questionnaire [3,6], *King's Brief Interstitial Lung Disease (KBILD)*

questionnaire [3,7], *EuroQol-5D-5L*, *Hospital Anxiety and Depression Scale (HADS)* [3],

Patient-Reported Outcomes Measurement Information System (PROMIS): *Sleep*

Disturbance (SD) and *Sleep-Related Impairment (SRI)*[8] and *Epworth Sleepiness Scale*

(ESS)[9]) and 6 clinical outcomes (*Forced Vital Capacity (FVC)*: *absolute* and *percent-*

predicted, *Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)*: *absolute* and

percent-predicted, *6-minute walk test (6MWT) distance, and the Gender-Age-*

Physiology (GAP) index). While the first five clinical outcomes were measured during

the trial, we also considered the GAP for this analysis. The GAP index is a validated

prognostic staging system for idiopathic pulmonary fibrosis patients. Correlations were

tested for significance cross-sectionally at baseline and at week 12. We performed

complete case analyses for each correlation, given the extent of missingness was

limited (ranging from 0 to 4). To control for multiple comparisons while maintaining the

exploratory nature of this pilot study, p-values were adjusted using the Benjamini-

Hochberg procedure [10] to control false discovery rate. Our findings are presented in

<u>Table 2.</u> All analyses used R (version 4.4.1).

We observed at baseline, patients demonstrated moderate disease burden with mean

predicted FVC of 74.8% (SD 21.44), predicted DLCO of 54.2% (SD 18.27), and 6MWT

distance of 1290 feet (SD 401.7). L-IPF cough and dyspnea reported mean scores of

26.3 (SD 24.2) and 23.0 (SD 21.9), respectively. K-BILD overall mean was 74.7 (SD

18.2), while HADS overall mean was 8.4 (SD 6.3).

We observed several statistically significant correlations (with false discovery rate $< =$

0.05) at both baseline and week 12. Quality of life measures of dyspnea and overall

disease impact reported by patients showed consistent correlations with clinical

measures: the L-IPF total score was negatively correlated with absolute FVC at

baseline ($r = -0.33$, adjusted $p = 0.03$) and at week 12 ($r = -0.42$, adjusted $p < 0.01$).

Similarly, the L-IPF total score was negatively correlated with 6MWT distance at

baseline ($r = -0.43$, adjusted $p < 0.01$) and week 12 ($r = -0.37$, adjusted $p = 0.02$).

Breathlessness-specific patient-reported outcomes also correlated significantly with

FVC, DLCO, 6MWT, and GAP at one or both time points. For example, the R-scale-PF

shortness of breath score showed negative correlations with absolute DLCO at baseline

($r = -0.35$, adjusted $p = 0.04$) and more strongly at week 12 ($r = -0.49$, adjusted

$p < 0.01$). The K-BILD Breathlessness and Activities score negatively correlated with

GAP score at baseline ($r = -0.42$, adjusted $p = 0.02$) and week 12 ($r = -0.40$, adjusted

$p = 0.02$). The K-BILD total score, where higher scores indicate better health status,

positively correlated with percent-predicted FVC at baseline ($r = 0.38$, adjusted $p =$

0.03) and week 12 ($r = 0.43$, adjusted $p < 0.01$). Finally, instruments assessing

psychological aspects (HADS), and sleep (PROMIS and ESS) generally showed

weaker or non-significant correlations with the clinical outcomes measured after false

discovery rate adjustment.

Our analysis underscores that certain patient-reported outcomes, particularly those

focused on respiratory symptoms like dyspnea, correlate with objective clinical

outcomes of lung function and exercise capacity and further capture distinct aspects of

the patient experience. The moderate strength of most observed correlations, even after

rigorous adjustment for multiple comparisons, suggests that patient-reported outcomes

provide unique, complementary information to clinical outcomes, rather than merely

reflecting the same constructs. This aligns with previous research suggesting that

patient-reported outcomes and clinical outcomes can offer different perspectives on a

patient's condition [1]. The application of the Benjamini-Hochberg procedure allowed us to

identify these relationships with controlled false discovery rate, which is particularly

suitable for hypothesis-generating research in pilot studies. The weaker correlations

observed for psychological and sleep-related patient-reported outcomes with

physiological measures highlight the multifaceted impact of idiopathic pulmonary

fibrosis, where these domains may be influenced by factors beyond those captured by

standard lung function tests. We acknowledge limitations for our study findings: small

sample size, single center study, and a short duration of follow up at only 12 weeks;

these issues may limit power to detect weaker correlations.

In conclusion, our analysis demonstrates that, in patients with idiopathic pulmonary

fibrosis, patient-reported outcomes relating to breathlessness and overall disease

impact show significant correlations with established clinical measures at baseline and

follow up at 12 weeks. The distinct patterns and strengths of these correlations

emphasize that patient-reported outcomes and clinical outcomes are not

interchangeable and offer complementary insights. This work supports the continued

integration of patient-reported outcomes alongside clinical outcomes in clinical trials and

practice to gain a complete understanding of idiopathic pulmonary fibrosis. Given the

observed correlation of patient-reported outcomes with conventional clinical measures

in idiopathic pulmonary clinical trials and practice – a strong rationale exists for utilizing

patient-reported outcomes as surrogate or primary endpoints in future studies to better

capture   patient-centric   benefits.

REFERENCES

1. Raghu G, Ghazipura M, Fleming TR, et al. Meaningful Endpoints for Idiopathic

Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on "Feels, Functions, Survives".

Report of a Collaborative Discussion in a Symposium with Direct Engagement from

Representatives of Patients, Investigators, the National Institutes of Health, a Patient

Advocacy Organization, and a Regulatory Agency. *Am J Respir Crit Care Med*.

2024;209(6):647-669. doi:10.1164/rccm.202312-2213SO

2. Holland AE, Dowman L, Smallwood N. Patient-reported Outcomes for Clinical Trials

in Idiopathic Pulmonary Fibrosis: New Opportunities to Understand How Patients

Feel and Function. *Am J Respir Crit Care Med*. 2020;202(12):1620-1622.

doi:10.1164/rccm.202007-2775ED

3. Kadura S, Purkayastha S, Benditt J, et al. Yoga Effect on Quality-of-Life Study Among

Patients with Idiopathic Pulmonary Fibrosis (YES-IPF). Published online May 21,

2025:2025.05.20.25327762. doi:10.1101/2025.05.20.25327762

4. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary

Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit*

Care Med. 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST

5. Swigris JJ, Andrae DA, Churney T, et al. Development and Initial Validation Analyses

of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. *Am J Respir Crit Care*

Med. 2020;202(12):1689-1697. doi:10.1164/rccm.202002-0415OC

6. Scallan C, Strand L, Hayes J, et al. R-scale for pulmonary fibrosis: a simple, visual

tool for the assessment of health-related quality of life. *Eur Respir J*.

2022;59(1):2100917. doi:10.1183/13993003.00917-2021

7. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's

Brief Interstitial Lung Disease (K-BILD) health status questionnaire. *Thorax.*

2012;67(9):804-810. doi:10.1136/thoraxjnl-2012-201581

8. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS[TM]

sleep disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med.*

2011;10(1):6-24. doi:10.1080/15402002.2012.636266

9. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness

scale. *Sleep.* 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

10.   Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and

Powerful Approach to Multiple Testing. *Source J R Stat Soc Ser B Methodol.*

1995;57(1):289-300.

 TABLES

192 **Table 1:** Mean (SD) [Count of Missing Measurements] of patient-reported and clinical

193 outcomes at baseline and week 12 in the YES-IPF trial (N=60). Lower scores indicate

194 better symptoms/quality of life for all outcomes except EuroQol-5D-5L scale, King's

195 Brief Interstitial Lung Disease scale, and the 6-minute walking test, where higher scores

196 indicate better status.

Outcome		Mean (SD) [# of missing]	
		Baseline	Week 12
Patient-reported outcome	Living with Idiopathic Pulmonary Fibrosis (L-IPF)		
	Cough	26.33 (24.20) [0]	21.61 (21.76) [1]
	Dyspnea	23.00 (21.94) [0]	22.08 (21.14) [1]
	Overall	28.67 (19.15) [0]	25.30 (18.26) [1]
	Raghu Scale for Pulmonary Fibrosis (R-scale-PF)		
	Cough	3.03 (2.42) [0]	2.60 (2.48) [2]
	Shortness of Breath	3.70 (2.57) [0]	3.83 (2.75) [2]
	Fatigue	4.05 (2.56) [0]	4.07 (2.97) [2]
	Mood	2.13 (2.33) [0]	1.69 (2.33) [2]
	Wellbeing	2.92 (1.95) [0]	3.34 (2.65) [2]
	Overall	15.83 (9.31) [0]	15.53 (10.33) [2]
	King's Brief Interstitial Lung Disease (K-BILD)		
	Psychological	38.30 (10.37) [0]	39.32 (9.62) [1]
	Breathlessness and Activities	24.80 (8.62) [0]	24.93 (7.86) [1]
	Chest Symptoms	11.48 (2.25) [0]	11.97 (2.14) [1]
	Overall	74.65 (18.15) [0]	76.22 (17.39) [1]
	EuroQol-5D-5L (EQ-5D-5L)		
	Visual Analogue Scale	0.81 (0.11) [0]	0.81 (0.14) [1]
	Index	71.05 (20.22) [0]	69.58 (19.26) [1]
	Hospital Anxiety and Depression Scale (HADS)		
	Anxiety	4.02 (3.47) [0]	3.41 (3.24) [2]
	Depression	4.37 (3.37) [0]	4.02 (3.49) [2]
	Overall	8.38 (6.30) [0]	7.41 (6.07) [2]
	Patient-Reported Outcomes Measurement Information System (PROMIS)		

	Sleep Disturbance	46.95 (9.57) [0]	46.04 (9.10) [2]
	Sleep-Related Impairment	45.97 (9.23) [0]	45.85 (9.37) [2]
	Epworth Sleepiness Scale (ESS)		
	Overall	5.83 (3.65) [0]	5.47 (4.01) [2]
	Forced Vital Capacity (FVC)		
	Absolute (L)	2.81 (0.82) [0]	2.68 (0.95) [1]
	Percent Predicted (%)	74.80 (21.44) [0]	73.80 (23.47) [1]
	Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO)		
Clinical outcome	Absolute (ml/min/kPa)	12.82 (3.93) [1]	11.78 (4.26) [4]
	Percent Predicted (%)	54.22 (18.27) [1]	51.09 (19.99) [4]
	6-minute walking test (6MWT)		
	Overall (feet)	1289.93 (401.68) [2]	1180.55 (459.16) [4]
	Gender-Age-Physiology (GAP) score		
	Overall	3.77 (1.48) [1]	3.77 (1.58) [4]

Table 2: Pearson correlation coefficients (p-values) between patient-reported outcomes and clinical at baseline and week 12 in patients with idiopathic pulmonary fibrosis. P-values are adjusted using the Benjamini-Hochberg method to control for false discovery rate across 21 patient-reported outcomes for each of the 6 clinical outcomes. * Indicates statistical significance at adjusted p<0.05.

	Forced Vital Capacity (FVC)				Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO)				6-minute walking test (6MWT) (feet)		Gender-Age-Physiology (GAP) score	
	Absolute (L)		*Pct. Predicted (%)*		*Absolute (L)*		*Pct. Predicted (%)*					
	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12
Living with Idiopathic Pulmonary Fibrosis (L-IPF)												
Cough	-0.25 (0.10)	-0.26 (0.07)	-0.30 (0.11)	-0.30 (0.04) *	-0.21 (0.18)	-0.19 (0.23)	-0.21 (0.18)	-0.15 (0.45)	-0.21 (0.17)	-0.13 (0.44)	0.22 (0.25)	0.13 (0.66)
Dyspnea	-0.36 (0.03) *	-0.53 (< 0.01) *	-0.28 (0.11)	-0.57 (< 0.01) *	-0.36 (0.04) *	-0.51 (< 0.01) *	-0.26 (0.18)	-0.35 (0.10)	-0.52 (< 0.01) *	-0.56 (< 0.01) *	0.31 (0.13)	0.47 (< 0.01)*
Overall	-0.33 (0.03) *	-0.42 (< 0.01) *	-0.25 (0.13)	-0.46 (< 0.01) *	-0.31 (0.07)	-0.33 (0.04) *	-0.23 (0.18)	-0.18 (0.35)	-0.43 (< 0.01) *	-0.37 (0.02) *	0.22 (0.25)	0.29 (0.12)
Raghu Scale for Pulmonary Fibrosis (R-scale-PF)												
Cough	-0.09 (0.62)	-0.15 (0.30)	-0.25 (0.13)	-0.15 (0.35)	-0.18 (0.25)	-0.05 (0.78)	-0.25 (0.18)	-0.04 (0.80)	-0.06 (0.74)	0.09 (0.55)	0.23 (0.25)	-0.03 (0.89)
Shortness of Breath	-0.33 (0.03) *	-0.49 (< 0.01) *	-0.32 (0.08)	-0.46 (< 0.01) *	-0.35 (0.04) *	-0.49 (< 0.01) *	-0.28 (0.18)	-0.34 (0.10)	-0.47 (< 0.01) *	-0.43 (< 0.01) *	0.30 (0.13)	0.36 (0.04)*
Fatigue	-0.14 (0.43)	-0.31 (0.04) *	-0.09 (0.62)	-0.21 (0.19)	-0.24 (0.13)	-0.34 (0.03) *	-0.22 (0.18)	-0.13 (0.47)	-0.36 (0.02) *	-0.31 (0.06)	0.12 (0.48)	0.10 (0.69)
Mood	-0.12 (0.50)	-0.19 (0.20)	0.05 (0.74)	-0.04 (0.78)	-0.07 (0.67)	-0.15 (0.35)	0.06 (0.68)	-0.04 (0.79)	-0.13 (0.42)	-0.12 (0.47)	-0.18 (0.34)	-0.08 (0.69)
Wellbeing	-0.33 (0.03) *	-0.35 (0.02) *	-0.21 (0.20)	-0.35 (0.02) *	-0.25 (0.13)	-0.31 (0.05)	-0.20 (0.20)	-0.25 (0.26)	-0.26 (0.10)	-0.30 (0.06)	0.18 (0.34)	0.15 (0.61)
Overall	-0.25 (0.10)	-0.38 (< 0.01) *	-0.21 (0.20)	-0.32 (0.03) *	-0.28 (0.09)	-0.35 (0.03) *	-0.23 (0.18)	-0.21 (0.31)	-0.33 (0.03) *	-0.29 (0.07)	0.17 (0.34)	0.14 (0.63)
King's Brief Interstitial Lung Disease (K-BILD)												

Psychological	0.26 (0.10)	0.29 (0.05)	0.29 (0.11)	0.28 (0.06)	0.14 (0.41)	0.24 (0.13)	0.07 (0.68)	0.18 (0.35)	0.25 (0.10)	0.18 (0.26)	-0.10 (0.57)	-0.09 (0.69)
Breathlessness and Activities	0.35 (0.03) *	0.44 (< 0.01) *	0.39 (0.03) *	0.51 (< 0.01) *	0.42 (0.02) *	0.43 (< 0.01) *	0.31 (0.18)	0.33 (0.10)	0.54 (< 0.01) *	0.44 (< 0.01) *	-0.42 (0.02)*	-0.40 (0.02)*
Chest Symptoms	0.14 (0.43)	0.26 (0.07)	0.20 (0.22)	0.37 (0.01) *	0.23 (0.15)	0.17 (0.31)	0.24 (0.18)	0.13 (0.47)	0.13 (0.42)	0.19 (0.26)	-0.13 (0.46)	-0.09 (0.69)
Overall	0.34 (0.03) *	0.39 (< 0.01) *	0.38 (0.03) *	0.43 (< 0.01) *	0.31 (0.07)	0.35 (0.03) *	0.22 (0.18)	0.26 (0.26)	0.42 (< 0.01) *	0.32 (0.05)	-0.27 (0.18)	-0.24 (0.24)
EuroQol-5D-5L (EQ-5D-5L)												
Visual Analogue Scale	0.28 (0.09)	0.35 (0.02) *	0.26 (0.13)	0.36 (0.02) *	0.25 (0.13)	0.33 (0.03) *	0.22 (0.18)	0.21 (0.31)	0.33 (0.03) *	0.44 (< 0.01) *	-0.26 (0.19)	-0.29 (0.12)
Index	0.34 (0.03) *	0.38 (< 0.01) *	0.19 (0.25)	0.39 (< 0.01) *	0.30 (0.07)	0.34 (0.03) *	0.16 (0.31)	0.24 (0.26)	0.49 (< 0.01) *	0.46 (< 0.01) *	-0.11 (0.51)	-0.16 (0.56)
Hospital Anxiety and Depression Scale (HADS)												
Anxiety	-0.05 (0.75)	-0.35 (0.02) *	0.09 (0.62)	-0.20 (0.22)	0.09 (0.67)	-0.15 (0.36)	0.22 (0.18)	-0.05 (0.79)	-0.09 (0.63)	-0.19 (0.26)	-0.20 (0.30)	-0.02 (0.90)
Depression	-0.17 (0.34)	-0.15 (0.30)	0.01 (0.95)	-0.10 (0.52)	-0.22 (0.16)	-0.27 (0.09)	-0.10 (0.54)	-0.18 (0.35)	-0.32 (0.03) *	-0.30 (0.06)	0.07 (0.69)	0.08 (0.69)
Overall	-0.12 (0.50)	-0.28 (0.06)	0.05 (0.74)	-0.16 (0.32)	-0.07 (0.67)	-0.24 (0.14)	0.07 (0.68)	-0.13 (0.47)	-0.22 (0.16)	-0.28 (0.08)	-0.07 (0.67)	0.04 (0.89)
Patient-Reported Outcomes Measurement Information System (PROMIS)												
Sleep Disturbance	-0.07 (0.70)	-0.11 (0.43)	-0.09 (0.62)	-0.00 (0.99)	-0.01 (0.93)	-0.01 (0.94)	-0.06 (0.68)	0.04 (0.79)	0.03 (0.90)	0.08 (0.60)	-0.05 (0.75)	-0.18 (0.50)
Sleep-Related Impairment	-0.02 (0.91)	-0.22 (0.13)	0.10 (0.62)	-0.11 (0.50)	0.08 (0.67)	-0.04 (0.81)	0.16 (0.31)	0.09 (0.64)	-0.01 (0.95)	-0.10 (0.55)	-0.13 (0.46)	-0.11 (0.69)
Epworth Sleepiness Scale (ESS)												
Overall	0.02 (0.91)	-0.09 (0.51)	-0.05 (0.74)	-0.11 (0.50)	0.03 (0.84)	0.11 (0.50)	0.11 (0.54)	0.24 (0.26)	-0.01 (0.95)	0.06 (0.66)	0.02 (0.89)	-0.03 (0.89)

2